Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1046 Plus Anticancer Agents in Advanced Endometrial Cancer
2022-502453-33-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of acasunlimab and pembrolizumab in endometrial cancer (EC) (2 cohorts), sponsored by Genmab. Primary endpoint: Objective response rate. Started Feb 2024; status: completed.
02
Drugs
acasunlimabpembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2022-502453-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502453-33-00.